Efficacy Of Intravitreal Ranibizumab And Conbercept For The Treatment Of Macular Edema Secondary To Branch Retinal Vein Occlusion

Objective:To observe and compare the therapeutic efficacy of intravitreal injection of ranibizumab and conbercept for the treatment macular edema secondary to branch retinal vein occlusion.Methods: This study is a prospective cohort study,including 43 patients from June 2017 to January 2018,who were diagnosed with branch retinal vein occlusion with macular edema in Shengjing hospital.We divided the patients into two groups,group A and group B.The eyes in group A got intravitreal injection of rannibizumb 0.5mg/0.05 ml.The eyes in group B got intralvitreal injection of conbercept 0.5mg/0.05 ml.After an initial intravitreal injection of either conbercept or ranibizumab,a pro re nata(PRN)strategy was adopted based on loss of visual acuity(VA)or increase in CMT.BCVA?CMT?IOP ?injection times and adverse events were recorded at pre-treated,1 week,1 month,2 month and 3 month after injection.The patients whose FFA displayed no perfusion areas got photocoagulation treatment.Results:There were 32 eyes in group A,11 eyes in group B,17 males and 21 females in this study.The mean BCVA(Log MAR)were 0.76±0.49?0.53±0.33?0.44±0.33?0.49±0.36?0.45±0.33 in group A,and0.52±0.26?0.32±0.17?0.25±0.27?0.24±0.17?0.27±0.20 in group B at pre-treated,1 week,1 month,2 month and 3 month after injection.The mean BCVA in two groups after injection were both improved compared with pre-treated statistically(P<0.05).There was no significant difference in improvement of BCVA after injection between ranibizumab and conbercept.The mean CMTs were670.19±184.12um?467.86±146.19um?381.69±119.91um?414.66±164.79um?361.48±121.37 um in group A,and 621.45±237.74um?352.70±110.09um?331.60±108.33um?305.60±65.80um?306.57±76.39 um in group B at pre-treated,1 week,1 month,2 month and 3 month after injection.The mean CMT in two groups after injection were both declined compared with pre-treated statistically(P<0.05).There was no significant difference in decline of CMT after injection between ranibizumab and conbercept.The injection time in group A is1.53±0.57 and in group B is1.27±0.47.There was only one eye complicated with conjunctival hemorrage and one eye with transient improving of IOP.No eyes suffered from severe complication like cataract,retina detachment and endophthalmitis.Conclusion:Both ranibizumab and conbercept intralvitreal injection can improve BCVA and decline CMT in patients with macular edema secondary to BRVO.There is no significant difference in decline of CMT and improvement of BCVA at each time after injection between them.It is safe to get intralvitreal injection of ranibizumab and conbercept causing no severe adverse events were observed in this study.